Objective.-To determine the efficacy of high-volume anesthetic suboccipital nerve blocks (HVSON) for chronic cluster headache (CCH) and to define consistency of response over long-term use.
Cluster headache (CH) is a trigeminal autonomic cephalalgia marked by short-lived attacks of one-sided severe head pain with associated cranial autonomic symptoms and agitation. 1 Chronic cluster headache (CCH) is defined as CH attacks occurring for more than 1 year without remission or with remission periods lasting for less than 3 months. Cluster headache treatment is divided into acute, transitional preventive, and maintenance preventive. Cluster headache can be a very disabling condition, especially for those with CCH and if deemed medicinal treatment refractory. 2 Greater occipital nerve (GON) blockade (injection of an anesthetic with or without an added corticosteroid at a point 1/3 laterally along an imaginary line from the occipital protuberance to the mastoid process) and suboccipital blockade (injection location in the suboccipital fossa at a point 1/3 laterally along an imaginary line from the inion to the mastoid process) have both shown efficacy as transitional and even maintenance preventive therapy for CH. [3] [4] [5] [6] [7] The American Headache Society Cluster Headache evidence-based treatment guidelines has noted Level A evidence for suboccipital steroid injections as a CH preventive treatment. 8 There are scant data about the long-term efficacy/ consistency of repetitive GON/suboccipital blockade in CCH as a preventive treatment in medicinally treatment refractory patients. 6 Typical volumes of anesthetic utilized with GON/suboccipital blockade are 1-3 mL of lidocaine 1-2% or bupivacaine 0.25-0.5%. [3] [4] [5] [6] [7] [8] [9] Some studies have looked at corticosteroids alone as an injectant. 4, 7 Higher volumes of injected anesthetics have not been studied. The goal of the current investigation was to determine the efficacy of high-volume anesthetic suboccipital nerve blockade (HVSON) as a preventive therapy for medicinal treatment refractory CCH and to define consistency of response over long-term use. We hypothesize that higher volume injectants may provide a greater rate of pain freedom and longer duration of treatment response than lower volume injectants.
METHODS
This was an open label, observational, case series study. Patients with CCH (ICHD defined) who were evaluated at a dedicated headache clinic over a 7-year time period and injected on at least 2 separate occasions were used for analysis. A single provider did all of the injections. All patients were being seen for headache consultation and the injections were carried out as part of their treatment protocol. In regard to sample size rationale, all patients with CCH were potential candidates for the study and there was no consideration of a defined study sample size. HVSON as defined by the author consisted of a single injection of 9 mL of 1% lidocaine and 1 mL of triamcinolone 40 mg injected on the side of CH pain. The injection location was in the suboccipital fossa at a point 1/3 laterally along an imaginary line from the inion to the mastoid process. This location has been used previously in other injection studies of CH patients. 3, 4, 6, 7 The needle was inserted to the skull base and once the bone was touched, the injection was completed without deviation of the needle from side to side. Secondary to the amount of volume injected, an area of volume-based swelling was noted in the suboccipital region post procedure. This area of fluid retention would subside in about 10-15 minutes time and did not cause patient discomfort. Patients were injected while they were in a CH cycle. In reality, none of the study subjects were experiencing any remission periods and had not for at least 6-12 months prior to consultation. Tenderness at the suboccipital injection location was not needed or required. Of note, the majority of the patients did not have tenderness at site of pending injection. The initial injection normally took place at the consultation visit and after diagnosis of CCH was made or verified. Times for repeat injections were determined by the physician and patient and typically occurred a short time after the previous HVSON wore off or when the patient could no longer tolerate his/her headaches. Repeat injections had to be at intervals of at least 4 weeks. No patient had contraindications to HVSON including prior occipital-based surgeries or allergies to lidocaine or triamcinolone. No patient had a history of diabetes mellitus or cardiac arrhythmias.
STATISTICAL ANALYSIS
This was a descriptive study only so no statistical tests were utilized to interpret findings. Patient baseline CH attack frequency was an estimate. For this observational study there was no run in period with a diary to define exact headache attack frequency prior to the injections. However, as CH is so stereotypical in frequency of attacks, the attack occurrence rarely varies, so study subjects could readily note how attack frequency changed post procedure. The study was given exempt status by the Geisinger IRB.
RESULTS
This is the primary analysis of these data. Ten CCH patients were retrospectively studied (9 males, 1 female) with only one patient having no response with the first 2 injections (Table 1 ). All study subjects were deemed medicinal treatment refractory failing at least 4 documented CH preventives, while some failed up to 10 preventives (Table 1) . 10 Response to HVSON was defined as complete (no CH attacks), partial (had less frequent CH attacks than typical for that individual and/or same number of attacks but less intense or of shorter duration), or no response. The 9 patients who responded had complete resolution of their CH attacks while the blocks lasted, regardless of their baseline attack frequency. All study subjects noted CH attack relief within 24 hours of the suboccipital injection. Each study subject responder had positive headache relief with the initial 2 injections. The range of mean duration of pain freedom response to HVSON was 1.5-31 weeks with the longest duration of response being 44 weeks in 2 patients (Table 1) . Two patients had 1.5-2 weeks of mean duration response. The remainder had at least 4 weeks of mean duration response. The overall mean duration of pain freedom response was 10.3 weeks in the responders, while it was 9.3 weeks for all study subjects combined (responders and non-responders). At total of 85 injections were given across all responders. In regard to consistency of response, there were 5 patients who were injected serially for 2-4 years in duration (30x, 17x, 15x, 10x, and 3x, respectively) with a consistent response of 6 weeks, 4 weeks, 12 weeks, 4 weeks, and 31 weeks, respectively, after each injection. Response duration was very reliable per individual patient rarely altering within a 7-day loss of response time.
The patients continued to get serial injections because they were deemed preventive medicine treatment resistant and the injections provided a preventive effect which greatly improved their quality of life. The study subjects with the shortest duration of pain freedom response chose not to continue with serial injections. Only one patient continued on preventive medication with the serial HVSON and this was more for control of his hypertension and not for headache preventive effect as the medication was not helping his CH. The remainder of the study subjects were not on preventive medication as nothing had helped, while one patient tapered off prophylaxis with the beneficial effects of the injections. Of the patients who had the highest number of injections over the longest period of time, there were 1-2x for each that an injection did not work. This never occurred on successive injections and appeared to be more of an outlier issue. A summary of the patients who had the highest number of injections and/or longest response times are included in Table 1 . All preventives medications documented were prescribed to maximum tolerated doses based on either side effects or ineffectiveness.
The patients who had a shorter duration of pain freedom with serial blockade were offered consultation for more permanent pain procedures with pain anesthesiology and functional neurosurgery. Patient #3 became free with a GON stimulator and was followed for 2 years after stimulator placement. Patient #9 had a partial response to radiofrequency ablation of the C2 dorsal root ganglia (DRG) and sphenopalatine ganglion (SPG) with lowered CH pain intensity but no change in attack frequency and he still is requiring serial HVSON. Patient #10 has had significant improvement with combined radiofrequency ablation of the SPG and C2 DRG with consistent pain freedom for months at a time, thus not requiring further HVSON. Some of the patients did not seek the additional consultation based on costs of travel and or just being content with the serial injections. Finally, Patient #1 had a very prolonged effect with HVSON and after her second injection was able to taper off both her maintenance preventives and was pain free 11 months post injection. When her headaches did return she appeared to transition to episodic CH. Post hoc analysis of the data notes that a history of cigarette smoking did not appear to alter response to HVSON. Eight of the 10 CCH subjects were chronic current smokers and 7 out of the 8 responded to HVSON. The one non-responder was a smoker but one of the 2 longest duration responders was also a chronic smoker. In regard to gender there was only one woman in the study and she had a very positive response to the HVSON, actually having the second longest remission times with the procedure. In addition, she was the only study subject in which the injections appeared to change the natural history of the headaches as she transitioned from CCH to episodic CH. In regard to adverse events, the single patient who received the greatest number of injections developed a unilateral avascular necrosis of the hip. This did require surgery. His orthopedic surgeons did not preclude further injection therapy for his CH as they could not define a cause and effect relationship with the suboccipital injections. This patient continued with serial HVSON for 1 year after his avascular necrosis diagnosis until he received his GON stimulator, which provided complete pain freedom. His medical insurance carrier had initially denied the stimulator for 3 years while he was receiving his serial HVSON.
The remainder of the study subjects had no major or minor side effects. There was mild palpable bone loss (presumed from the use of corticosteroid in the injectant) at site of blockade in the patients who received multiple procedures, but this was not noticeable to the patient and was asymptomatic. No patient had any apparent major side effect from the highvolume lidocaine infiltrate including: seizures, agitation, confusion, altered level of consciousness, change in heart rate, or induction of arrhythmias. Fleeting mild lightheadedness of seconds to several minutes was a very rare issue post injection. All of the study subjects were quite content with getting serial blocks as their preventive treatment scheme, especially as the side effect profile of the procedures was almost non-existent.
DISCUSSION
The current investigation is the first to look at highvolume anesthetic suboccipital nerve blocks in the treatment of CH. In this case series only CCH patients were studied. The choice of using a higher volume anesthetic injectant has come from the author identifying improved response rates in both the CH and migraine populations vs traditional lower volume injectants. The use of both traditionally placed GON and suboccipital placed injections for CCH has been studied previously with customary lower volume anesthetic injectant amounts ( open label study in 83 CCH patients utilizing a suboccipital injection (methylprednisolone 80 mg and 2 mL of 2% lidocaine) every 3 months. After Round 1, 35/83 patients became pain free with duration of pain freedom of 15 days in 31%, 30 days in 15%, and 90 days in 2%. One patient remained pain free for 150 days. In regard to the consistency of response over 4 rounds of injections, a total of 10 patients had complete pain freedom to all nerve blocks. All showed benefit at day 15, while 30% did so at day 30 and none at day 90. The authors concluded that their technique showed a highly positive consistent response when blocks were done every 3 months and had reproducible response if the patient responded to the first injection. They documented no corticosteroid adverse events. When looking at the available studies utilizing GON/suboccipital nerve blocks with anesthetic for CCH and duration of complete pain freedom, most techniques provide less than 30 days, although there are outliers with longer response times ( Table 2) . [3] [4] [5] [6] The majority of these studies were using high-dose corticosteroids with minimal volume anesthetic as an injectant. The average duration of response in the present study utilizing HVSON was 65 days. In addition, the HVSON study subjects all achieved complete pain freedom during the response time of the injections. Thus, it appears that a higher volume anesthetic block may achieve a longer duration of effective response than a lesser volume procedure and possibly lead to a higher rate of pain freedom. The location of blockade (suboccipital vs traditional GON location) may also be important for response rates, but direct comparator trials are required. Why a higher volume anesthetic nerve block injection would last longer than a lower volume injection can only be hypothesized. Simply, could higher volumes of anesthetic working at the trigemino-cervical complex shut off input to the trigemino-autonomic complex more completely than lower volumes of anesthetic and thus lead to a longer duration of headache response in CH? 11 Could the high-volume suboccipital block be doing something more central outside of directly modulating trigemino-cervical transmission? 12 Possibly the higher volume injectant is able to modulate the trigemino-hypothalamic pathway, for example, thus inhibiting the primary generator of CH, while a lower volume of injectant has less effect on this anatomic route and thus less preventive duration of effect? 13 Finally, a higher volume injectant could act as a type of occipital nerve decompression modality with the liquid volume moving structures such as a vessel or scar tissue, which may be in contact with the GON, off the nerve. A primary GON generator for CH is not suggested for most CH patients (although this has been suggested for some in the literature), but as a large percentage of CH patients have had precedent head trauma prior to CH onset, GON compression could have some conceivable role in CH pathogenesis.
14 In regard to consistency of response, the current investigation and the study by Lambru et al 6 suggest that serial suboccipital injections can have a consistent effect over time and be utilized as a maintenance preventive even in patients who have been deemed medicinal treatment refractory. We cannot tell from our data if having a positive response to an initial block will always suggest response to serial blockade, but as all of our patients were required to have at least 2 injections to be included in our study and as all responders achieved pain freedom with both initial injections, this does seem to be a reasonable conclusion. The present technique of HVSON seems to deliver a long duration effect, a high rate of pain freedom, with consistency of response over time as study subjects have been followed for up to a 4-year time period. Another possible added benefit of HVSON is that it has a comparably much lower dosage of corticosteroid than other effective GON block techniques that have been utilized for CH, so the safety profile may also be superior (Table 2) . 15 The one patient who received the most injections over time did develop an avascular necrosis of the hip. Direct cause and effect was not established by orthopedic consultation but a link to injectable corticosteroids remains a possibility. This side effect has not been previously reported in the literature with injectable local corticosteroids for head pain. No other corticosteroid-based side effects were noted in any of the other study subjects. Secondary to the high volume of anesthetic being delivered to the suboccipital region, one potential complication could be occipital artery compression. If this does indeed occur with HVSON, it appears to be clinically asymptomatic at least in the patients that have been studied. Completing HVSON with ultrasound guidance could help avoid any potential issues with occipital artery manipulation and is a definite option for physicians to utilize. Limitations to the present study include the lack of a standard pain diary to define exact length of injection duration effect. The fact that all of the study subjects were seen recurrently around the time the injections wore off suggests a fairly reliable documented response time. As all patients received an injectant of both lidocaine and triamcinolone, it is not possible to state that a high-volume anesthetic block alone is as effective without the corticosteroid and, thus, is the corticosteroid needed to achieve the documented headache attack alleviation response and duration of response. Finally, this study was an open label, observational analysis and thus the data need to be interpreted with the limitations of open-label studies.
CONCLUSION
HVSON from this open label, observational, case series study appears to be effective in the preventive treatment of medicinal refractory CCH and shows consistent response over long-term use with high rates of pain freedom. A presumed added benefit of HVSON is the relatively low dosage of corticosteroid utilized vs other published GON-based injection techniques. Direct comparative trials vs lower volume traditional anesthetic GON/suboccipital blocks and corticosteroid only blocks are now needed to assess the true efficacy of the varying techniques. 
